1. Home
  2. EDBL vs OGEN Comparison

EDBL vs OGEN Comparison

Compare EDBL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

HOLD

Current Price

$3.37

Market Cap

3.6M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.69

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDBL
OGEN
Founded
2020
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
EDBL
OGEN
Price
$3.37
$0.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
229.5K
178.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.57
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.56
N/A
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.11
52 Week High
$7.54
$9.16

Technical Indicators

Market Signals
Indicator
EDBL
OGEN
Relative Strength Index (RSI) 70.20 42.15
Support Level $3.25 $0.62
Resistance Level $3.98 $0.72
Average True Range (ATR) 0.64 0.07
MACD 0.04 -0.00
Stochastic Oscillator 43.66 34.09

Price Performance

Historical Comparison
EDBL
OGEN

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: